Assessing IQVIA Holdings (IQV) Valuation After Expanded AI Clinical Trial Collaboration With Kexing Biopharm

Simply Wall St.05-14 14:52

IQVIA Holdings (IQV) is back in focus after expanding its collaboration with Kexing Biopharm to use AI-enabled clinical trial tools across a global, multi product biosimilar program, drawing fresh ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635799196?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/137473239-main-header/1756256222159","is_english":true,"pubTime":"2026-05-14 14:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635799196","market":"hk","top_or_hot":-1,"title":"Assessing IQVIA Holdings (IQV) Valuation After Expanded AI Clinical Trial Collaboration With Kexing Biopharm","media":"Simply Wall St.","content":"<div>\n<p>IQVIA Holdings (IQV) is back in focus after expanding its collaboration with Kexing Biopharm to use AI-enabled clinical trial tools across a global, multi product biosimilar program, drawing fresh ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/assessing-iqvia-holdings-iqv-valuation-after-expanded-ai-cli\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing IQVIA Holdings (IQV) Valuation After Expanded AI Clinical Trial Collaboration With Kexing Biopharm</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing IQVIA Holdings (IQV) Valuation After Expanded AI Clinical Trial Collaboration With Kexing Biopharm\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-14 14:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/assessing-iqvia-holdings-iqv-valuation-after-expanded-ai-cli><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IQVIA Holdings (IQV) is back in focus after expanding its collaboration with Kexing Biopharm to use AI-enabled clinical trial tools across a global, multi product biosimilar program, drawing fresh ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/assessing-iqvia-holdings-iqv-valuation-after-expanded-ai-cli\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1201861165.SGD","symbol_name":"Natixis Harris Associates Global Equity PA SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/assessing-iqvia-holdings-iqv-valuation-after-expanded-ai-cli","article_id":"2635799196","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/137473239-main-header/1756256222159"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/assessing-iqvia-holdings-iqv-valuation-after-expanded-ai-cli","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2635799196","pubTimestamp":1778741565,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"IQVIA Holdings (IQV) is back in focus after expanding its collaboration with Kexing Biopharm to use AI-enabled clinical trial tools across a global, multi product biosimilar program, drawing fresh attention to the stock.\nSee our latest analysis for IQVIA Holdings.\nThe stock’s 1 day share price return declined 1.53% to $172.38, extending a 7 day share price pullback of 2.32%. However, the 1 year total shareholder return of 21.55% contrasts with weaker multi year outcomes and indicates that...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","BK4023":"应用软件","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","BK4543":"AI","BK4121":"生命科学工具和服务","LU0882574055.USD":"富达全球健康医疗A ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","AIPO":"Defiance AI and Power Infrastructure ETF","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","BK4588":"碎股","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","BK4530":"医药外包概念","AGIX":"通用人工智能 ETF-AGIX","IQV":"艾昆纬","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4528":"SaaS概念","AI":"C3.ai, Inc.","BK4587":"ChatGPT概念","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","BK4551":"寇图资本持仓","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD"},"translate_title":"与科兴生物扩大人工智能临床试验合作后评估IQVIA Holdings(IQV)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIYY":0.6,"AI":0.9,"ARTY":1.5,"AGIX":1.5,"IQV":1.5,"AIPO":1.5,"CHAT":1.5},"content_text":"IQVIA Holdings (IQV) is back in focus after expanding its collaboration with Kexing Biopharm to use AI-enabled clinical trial tools across a global, multi product biosimilar program, drawing fresh attention to the stock. See our latest analysis for IQVIA Holdings. The stock’s 1 day share price return declined 1.53% to $172.38, extending a 7 day share price pullback of 2.32%. However, the 1 year total shareholder return of 21.55% contrasts with weaker multi year outcomes and indicates that momentum has recently been rebuilding from a lower base. If AI in clinical trials is on your radar, it could be a good time to broaden your watchlist with other healthcare focused AI opportunities via the 33 healthcare AI stocks. With IQVIA trading at $172.38, alongside an indicated intrinsic discount of about 45% and a 1 year total return of 21.55%, is the stock still underappreciated, or is the market already pricing in years of future growth? AdvertisementMost Popular Narrative: 25.6% Undervalued IQVIA’s most followed narrative points to a fair value of $231.60 against the last close of $172.38, framing a sizeable potential valuation gap built on earnings and cash flow assumptions.  Accelerated adoption of AI-driven analytics and data solutions, supported by strong client demand and high-profile industry partnerships like NVIDIA, positions IQVIA for improved operational efficiency, faster project execution, and differentiation, which should support future revenue growth and eventual margin expansion as AI capabilities scale.  Read the complete narrative. Curious how this narrative gets to that higher fair value? It leans on steady revenue gains, firmer margins, and a future earnings profile that commands a richer multiple. The exact mix of growth rates, profitability and discounting is where the real story sits. Result: Fair Value of $231.60 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, pressure on CRO pricing and high leverage could squeeze margins and flexibility, especially if clients slow project decisions or push harder on contract terms. Find out about the key risks to this IQVIA Holdings narrative. Next Steps Given the mix of optimism around AI tools and concern about leverage and pricing, it helps to review the data yourself and act quickly while this story is still taking shape. You can start with the 5 key rewards and 1 important warning sign. Looking for more investment ideas? If IQVIA has your attention, do not stop here. Use the Simply Wall St Screener to quickly surface fresh stock ideas before other investors catch on.  Target potential value opportunities by scanning for companies that look mispriced relative to fundamentals through the 47 high quality undervalued stocks. Strengthen your defensives by focusing on companies with sturdy finances using the solid balance sheet and fundamentals stocks screener (45 results). Get ahead of the crowd by searching for lesser known opportunities with solid metrics in the screener containing 23 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635799196","isCrawlerRequest":true}